Listing provides funding for Tissue Regenix

By The Newsroom
Published 29th Jun 2010, 23:13 BST
Updated 29th Jun 2010, 23:13 BST
BIOTECH company Tissue Regenix said it now has the funds to capitalise on growing demand for replacement body parts after marking its first day as a listed company.

The York-based group, which was spun out of the University of Leeds, joined the Alternative Investment Market (AIM) via the reverse takeover of technology firm Oxeco.

Tissue's unique technology, dCELL, removes cells from human and animal body parts to create a scaffold which can be used to replace worn out or diseased body parts, without the need for anti-rejection drugs.

Hide Ad